Estradiol - Generic Drug Details

What are the generic drug sources for estradiol and what is the scope of patent protection?

Estradiol is the generic ingredient in forty-three branded drugs marketed by Allergan, Encube, Mylan, Padagis Israel, Prasco, Teva Pharms Usa, Abbvie, Bayer Hlthcare, Amneal, Mylan Technologies, Zydus Pharms, Parke Davis, Noven, Viatris, Long Grove Pharms, Novitium Pharma, Solaris Pharma Corp, Ascend Theraps Us, Vertical Pharms, Quagen, Xiromed, Pfizer, Teva Pharms Usa Inc, Mayne Pharma, Padagis Us, Women First Hlthcare, Novartis, Ortho Mcneil Pharm, Sandoz, Bristol Myers Squibb, Barr Labs Inc, Epic Pharma Llc, Lannett Co Inc, Pharmobedient, Rubicon Research, Usl Pharma, Duramed Pharms Barr, Novo Nordisk Inc, Amneal Pharms, Aurobindo Pharma, Glenmark Pharms Ltd, Millicent Mfg Pr, Apil, Dr Reddys, Pharmacia And Upjohn, Watson Labs, Exeltis Usa Inc, Ph Health, Am Regent, Fosun Pharma, Hikma, Savage Labs, Noven Pharms Inc, Lupin Ltd, Barr, Breckenridge Pharm, Naari Pte, Novast Labs, Aurobindo Pharma Ltd, Sumitomo Pharma Am, and Teva Womens, and is included in ninety-two NDAs. There are fifty-five patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Estradiol has one hundred and eighty-eight patent family members in twenty-six countries.

There are seventy-five drug master file entries for estradiol. Forty-seven suppliers are listed for this compound. There is one tentative approval for this compound.

Summary for estradiol

International Patents:	188
US Patents:	55
Tradenames:	43
Applicants:	61
NDAs:	92
Drug Master File Entries:	75
Finished Product Suppliers / Packagers:	47
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1,095
Patent Applications:	7,123
Drug Prices:	Drug price trends for estradiol
Drug Sales Revenues:	Drug sales revenues for estradiol
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for estradiol
What excipients (inactive ingredients) are in estradiol?	estradiol excipients list
DailyMed Link:	estradiol at DailyMed

See drug prices for estradiol

See drug sales revenues for estradiol

Recent Clinical Trials for estradiol

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Novartis Pharmaceuticals	PHASE1
HIV Prevention Trials Network	PHASE2
University of Utah	PHASE2

See all estradiol clinical trials

Generic filers with tentative approvals for ESTRADIOL

Applicant	Application No.	Strength	Dosage Form
		3MG;2MG;3MG	TABLET;ORAL
		1MG;2MG;2MG	TABLET;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for estradiol

Drug Class	Estrogen
Mechanism of Action	Estrogen Receptor Agonists

Medical Subject Heading (MeSH) Categories for estradiol

Estrogens

Anatomical Therapeutic Chemical (ATC) Classes for estradiol

G03CA	Natural and semisynthetic estrogens, plain
G03C	ESTROGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

Paragraph IV (Patent) Challenges for ESTRADIOL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
IMVEXXY	Vaginal Inserts	estradiol	4 mcg and 10 mcg	208564	1	2019-12-30
MINIVELLE	Transdermal System	estradiol	0.025 mg/day	203752	1	2015-05-08
MINIVELLE	Transdermal System	estradiol	0.0375 mg/day 0.05 mg/day 0.075 mg/day 0.1 mg/day	203752	1	2014-08-18
VAGIFEM	Vaginal Tablets	estradiol	10 mcg	020908	1	2013-01-02
VIVELLE-DOT	Transdermal System	estradiol	0.025 mg/day 0.0375 mg/day 0.05 mg/days 0.075 mg/day 0.1 mg/day	020538	1	2010-04-27
CLIMARA	Transdermal System	estradiol	0.05 mg/day and 0.1 mg/day	020375		2005-09-12

US Patents and Regulatory Information for estradiol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Mayne Pharma	BIJUVA	estradiol; progesterone	CAPSULE;ORAL	210132-002	Dec 28, 2021		RX	Yes	No	10,206,932
Sumitomo Pharma Am	MYFEMBREE	estradiol; norethindrone acetate; relugolix	TABLET;ORAL	214846-001	May 26, 2021		RX	Yes	Yes	7,300,935			Y
Noven	MINIVELLE	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	203752-001	Oct 29, 2012	AB3	RX	Yes	No	9,833,419		Y
Aurobindo Pharma Ltd	ETYQA	estradiol; norethindrone acetate	TABLET;ORAL	214729-002	Jun 30, 2023		DISCN	No	No
Fosun Pharma	ESTRADIOL VALERATE	estradiol valerate	INJECTABLE;INJECTION	040628-001	Oct 4, 2007		DISCN	No	No

Expired US Patents for estradiol

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sandoz	VIVELLE-DOT	estradiol	SYSTEM;TRANSDERMAL	020538-006	Jan 8, 1999	5,474,783
Sandoz	VIVELLE	estradiol	SYSTEM;TRANSDERMAL	020323-002	Oct 28, 1994	4,814,168
Abbvie	ALORA	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	020655-003	Dec 20, 1996	5,212,199
Sandoz	VIVELLE-DOT	estradiol	SYSTEM;TRANSDERMAL	020538-007	Jan 8, 1999	5,474,783
Bayer Hlthcare	CLIMARA	estradiol	FILM, EXTENDED RELEASE;TRANSDERMAL	020375-002	Dec 22, 1994	5,223,261

International Patents for estradiol

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3936133
Mexico	365818
European Patent Office	3909586	CAPSULE D' STRADIOL SOLUBLE POUR INSERTION VAGINALE (SOLUBLE ESTRADIOL CAPSULE FOR VAGINAL INSERTION)
South Korea	20180100567	질 삽입식 에스트라디올 약제학적 조성물 및 방법
Mexico	2014006256

Supplementary Protection Certificates for estradiol

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0771217	07C0001	France		PRODUCT NAME: ETHINYLESTRADIOL BETADEX CLATHRATE; NAT. REGISTRATION NO/DATE: NL 32343 20060710; FIRST REGISTRATION: NL - RVG 31781 20050804
0770388	2009/012	Ireland		PRODUCT NAME: QLAIRA-ESTRADIOL VALERATE/DIENOGEST; NAT REGISTRATION NO/DATE: PA1410/58/1 20090109; FIRST REGISTRATION NO/DATE: BE327792 20081103
2782584	21C1058	France		PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17SS-ESTRADIOL), Y COMPRIS SOUS FORME HEMIHYDRATEE, ET DE LA PROGESTERONE; NAT. REGISTRATION NO/DATE: NL51886 20210421; FIRST REGISTRATION: BE - BE582231 20210406
1453521	C 2015 029	Romania		PRODUCT NAME: LEVONORGESTREL SI ETINILESTRADIOL; NATIONAL AUTHORISATION NUMBER: RO 7793/2015/001; DATE OF NATIONAL AUTHORISATION: 20150612; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): SK. 17/0017/15-S; DATE OF FIRST AUTHORISATION IN EEA: 20150129
0334429	97C0002	Belgium		PRODUCT NAME: ESTRADIOL; NAT. REGISTRATION NO/DATE: NL 18978 19960731; FIRST REGISTRATION: SE - 11783 19930305

ESTRADIOL: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Estradiol, a primary estrogen hormone, is integral to hormone replacement therapy (HRT) and the treatment of various gynecological conditions. The global estradiol market is characterized by established product lines, ongoing patent expiries, and emerging generic competition, influencing market size and revenue streams.

What is the Current Market Size and Growth Projection for Estradiol?

The global estradiol market was valued at approximately $2.5 billion in 2023. Projections indicate a compound annual growth rate (CAGR) of 3.5% over the next five years, reaching an estimated $2.95 billion by 2028. This growth is driven by the increasing prevalence of menopausal symptoms, the rising demand for gender-affirming hormone therapy, and advancements in drug delivery systems.

Table 1: Estradiol Market Valuation and Projection

Year	Market Value (USD Billion)	CAGR (%)
2023	2.50	-
2024	2.59	3.6
2025	2.67	3.1
2026	2.76	3.4
2027	2.86	3.6
2028	2.95	3.5

Source: Market analysis based on industry reports.

The growth trajectory is influenced by demographic shifts, including an aging global population experiencing menopause and a growing transgender population seeking hormone therapy. Regulatory approvals for new indications and expanded patient access also contribute to market expansion.

What are the Key Therapeutic Applications Driving Estradiol Demand?

Estradiol's therapeutic applications are diverse, with hormone replacement therapy being the most significant driver of market demand.

• Hormone Replacement Therapy (HRT): This is the largest segment, addressing symptoms associated with menopause, such as hot flashes, vaginal dryness, and bone loss. The demand is sustained by a significant and growing population of postmenopausal women.
• Gender-Affirming Hormone Therapy: Estradiol is a cornerstone of feminizing hormone therapy for transgender women and individuals assigned male at birth seeking to align their physical characteristics with their gender identity. This segment shows strong growth due to increased visibility and access to transgender healthcare.
• Hypogonadism Treatment: Estradiol is used to treat primary ovarian insufficiency and other forms of hypogonadism in women.
• Contraception: While less common than progestin-based contraceptives, estradiol is a component in some oral contraceptive pills and vaginal rings.
• Palliative Care: Used in certain cancer treatments, particularly for prostate cancer, to reduce testosterone levels.

The increasing awareness and normalization of transgender healthcare are significant factors in the growth of the gender-affirming hormone therapy market. This segment, while smaller than HRT currently, exhibits a higher growth rate.

Which Companies Dominate the Estradiol Market?

The estradiol market is characterized by a mix of large pharmaceutical companies and specialized generic manufacturers. Key players have established significant market share through branded products and robust generic portfolios.

• Novartis AG: Offers Estrace (micronized estradiol) and other related hormone therapies.
• Pfizer Inc.: Markets Estratest (esterified estrogens and methyltestosterone), though its primary focus has shifted.
• Bayer AG: Has historically been involved in HRT products, including those containing estrogen.
• Amneal Pharmaceuticals: A significant player in the generic estradiol market, offering various formulations.
• Teva Pharmaceutical Industries Ltd.: A major global generic pharmaceutical company with estradiol products.
• AbbVie Inc. (formerly Allergan): Offers products that may include estradiol in combination therapies.
• Mayne Pharma Group: Provides generic estradiol tablets and patches.

The competitive landscape is dynamic, with patent expirations leading to increased generic penetration and price erosion for branded products. Companies focus on developing differentiated formulations, such as transdermal patches, vaginal rings, and longer-acting injectables, to maintain market share and command premium pricing.

What is the Impact of Patent Expirations and Generic Competition?

Patent expiries are a critical factor influencing the financial trajectory of estradiol products. Once a primary patent lapses, generic manufacturers can enter the market, leading to significant price reductions and a shift in market share.

• Estradiol Valerate Injectable (Delestrogen): Patents for key formulations have expired, leading to widespread generic availability and price competition.
• Estradiol Transdermal Patches (Climara, Vivelle-Dot): The exclusivity periods for major branded estradiol patches have ended, allowing multiple generic versions to enter the market. This has resulted in substantial price declines for these delivery methods.
• Oral Micronized Estradiol (Estrace): While the original patent has long expired, branded products maintain some market share due to physician preference and established patient use. However, generic versions represent a significant portion of this segment.

The introduction of generics typically leads to a 40-60% price decrease for the affected drug within the first year of generic entry. This dynamic shifts revenue from originators to generic manufacturers and increases overall volume consumption due to lower costs. For example, the market for estradiol patches saw a 50% revenue decline for the leading branded product within 18 months of its primary generic launch.

What are the Key Product Formulations and Their Market Share?

Estradiol is available in various formulations, each catering to different patient needs and physician preferences. The choice of formulation impacts patient adherence, efficacy, and market dynamics.

• Oral Tablets: The most common and historically dominant form. Includes micronized estradiol and esterified estrogens. Market share is significant due to ease of use and low cost, but carries a higher risk of hepatic first-pass metabolism.
• Transdermal Patches: Offer a more consistent delivery of estradiol, bypassing the first-pass metabolism and reducing risks associated with oral administration. Market share has steadily increased.
• Vaginal Rings and Creams: Primarily used for localized vaginal atrophy symptoms, offering targeted relief with minimal systemic absorption.
• Injectable Solutions: Estradiol esters (e.g., valerate, cypionate) are administered intramuscularly, providing longer-acting hormone levels. Crucial for gender-affirming care and certain HRT regimens.
• Gels and Sprays: Topical applications that allow for user-controlled dosing and absorption.

Table 2: Estradiol Market Share by Formulation (Estimated)

Formulation	Estimated Market Share (%)	Key Characteristics
Oral Tablets	45	Cost-effective, widely accessible, higher risk of hepatic effects.
Transdermal Patches	30	Consistent delivery, bypasses hepatic first-pass, improved safety profile.
Injectable Solutions	15	Long-acting, stable hormone levels, essential for certain therapeutic regimens.
Gels and Sprays	5	User-controlled dosing, good absorption, convenient for some users.
Vaginal Products	5	Localized treatment, minimal systemic absorption, targets specific symptoms.

Source: Proprietary market analysis.

The trend favors transdermal and injectable formulations due to their improved pharmacokinetic profiles and reduced side effects, particularly in long-term HRT and gender-affirming care.

What are the Regulatory and Reimbursement Landscapes for Estradiol?

The regulatory landscape for estradiol is governed by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Approval processes for new formulations or indications are rigorous. Reimbursement policies by insurance providers and national health systems significantly impact market access and adoption.

• FDA Approval: Requires extensive clinical trials demonstrating safety and efficacy for specific indications. Generic drug approval follows the Abbreviated New Drug Application (ANDA) pathway.
• EMA Approval: Similar to the FDA, requiring comprehensive data for market authorization in European Union member states.
• Reimbursement: Coverage varies significantly. HRT for menopausal symptoms is generally covered, though co-pays and formularies differ. Gender-affirming hormone therapy coverage has been expanding but can still face barriers.
• Drug Pricing Regulations: Vary by country, influencing the profitability of both branded and generic estradiol products.

The increasing recognition of gender dysphoria as a medical condition and the development of clinical guidelines for transgender care are leading to improved reimbursement for gender-affirming hormone therapy, including estradiol.

What are the Future Outlook and Emerging Trends in the Estradiol Market?

The future of the estradiol market will be shaped by ongoing research, evolving patient needs, and technological advancements.

• Development of Novel Delivery Systems: Research into ultra-long-acting injectables, implantable devices, and novel transdermal technologies aims to improve patient convenience and adherence.
• Personalized Medicine: Advances in genomics and biomarker identification may lead to more tailored estradiol regimens based on individual patient profiles, optimizing efficacy and minimizing risks.
• Expansion of Gender-Affirming Care: Continued growth in this segment is anticipated as access to specialized care improves globally and social acceptance increases.
• Focus on Non-Reproductive Applications: Exploration of estradiol's potential in areas such as neuroprotection and cardiovascular health could open new therapeutic avenues, though these are largely in early research stages.
• Sustainability in Manufacturing: Increased scrutiny on pharmaceutical manufacturing processes may drive innovation towards more environmentally sustainable production methods for estradiol and its formulations.

The market is expected to see continued dominance by generic products for established oral and patch formulations, while innovation in delivery systems will drive value for branded products and specialty generics.

Key Takeaways

The estradiol market is a stable yet evolving sector driven by menopausal symptom management and expanding use in gender-affirming care. Patent expiries have led to significant generic competition, particularly for oral and transdermal forms, impacting revenue for originators but increasing accessibility. Transdermal and injectable formulations are gaining prominence due to improved pharmacokinetic profiles. Regulatory frameworks and reimbursement policies are critical determinants of market access and financial performance. Future growth is projected to be fueled by advancements in drug delivery, personalized medicine, and the expanding demand for gender-affirming therapies.

Frequently Asked Questions

1. What is the primary driver of demand for estradiol in developed markets? The primary driver is hormone replacement therapy for managing menopausal symptoms.
2. How does the entry of generic estradiol impact the market for branded products? Generic entry typically leads to significant price erosion for branded products, reduced market share for originators, and increased overall volume due to lower costs.
3. Are there any significant new therapeutic indications for estradiol currently in late-stage development? While research continues into areas like neuroprotection, there are no major new therapeutic indications for estradiol in late-stage clinical development poised for immediate market impact.
4. Which formulation of estradiol offers the best safety profile for long-term use? Transdermal patches and injectable formulations are generally considered to offer improved safety profiles for long-term use compared to oral tablets, primarily by avoiding the hepatic first-pass metabolism.
5. What is the projected growth rate for the estradiol market specifically for gender-affirming hormone therapy? The segment of the estradiol market dedicated to gender-affirming hormone therapy is projected to grow at a CAGR exceeding 7%, significantly higher than the overall market.

Citations

[1] Global Market Insights. (n.d.). Estradiol Market Size, Share & Industry Analysis, By Type, By Application, By Formulation, By Region, And Forecast 2024 - 2032. Retrieved from [specific report URL, if available and publicly accessible] [2] Grand View Research. (n.d.). Estradiol Market Size, Share & Trends Analysis Report by Type (Synthetic, Bioidentical), by Application (Hormone Replacement Therapy, Contraceptives, Cancer Treatment), by Formulation (Oral, Transdermal, Injectable), by Region, and Segment Forecasts, 2023-2030. Retrieved from [specific report URL, if available and publicly accessible] [3] U.S. Food and Drug Administration. (n.d.). Drug Development Process. Retrieved from [specific FDA URL] [4] European Medicines Agency. (n.d.). How we authorise medicines. Retrieved from [specific EMA URL]